medigraphic.com

2012, Number 4

<< Back Next >>

Rev Fac Med UNAM 2012; 55 (4)

Neuroprotection and traumatic brain injury

Estrada RF, Morales GJ, Tabla RE, Solís LB, Navarro AHA, Martínez VM, Pérez AA, González RR, Rodríguez SLE, Navarro L

Language: Spanish
References: 45
Page: 16-29
PDF size: 328.01 Kb.


ABSTRACT

During a process of brain injury, e.g. head injury, responses to induce brain damage and/or cell death are activated, but also protective responses that attempt to maintain the integrity and functionality of the brain are induced. This is known as neuroprotection. Indeed a head injury triggers mechanisms that result in release of excitatory neurotransmitters such as glutamate, which causes an influx of Ca2+ into neurons, activation of proteases, lipases, nitric oxide synthase, endonucleases, free radicals production and potentially necrosis and/or apoptosis. Although the brain or neuroprotective substances research has more than 50 years, is at the end of the decade of 80’s of last century when it began to appear a large number of publications trying to understand the neuroprotective mechanisms triggered by an insult to the brain. In this paper we briefly review the concept, epidemiology and strategies that have been used to minimize the damage caused by brain injury.


REFERENCES

  1. Jain KK. Handbook of Neuroprotection: Humana Press, 2011 p 1.

  2. Leonard AL. History of Neuroprotection and Rationale as a Therapy for Glaucoma. Am J Manag Care. 2008;14:S11-S14.

  3. Leker RR, Shohami E. Cerebral ischemia and trauma-different etiologies yet similar mechanisms: neuroprotective opportunities Brain Research Reviews. 2002;39:55-73.

  4. Menon K, Schwab K, Wright DW, Maas AI. Position Statement: Definition of Traumatic Brain Injury. Arch Phys Med Rehabil. 2010;91:1637-40.

  5. Sistema Nacional de Vigilancia Epidemiológica. Aspectos clínicos y epidemiológicos del Trauma Craneoencefálico en México. Secretaría de Salud 2008;25:1-4.

  6. Chen AY, Colantonio A. Defining neurotrauma in administrative data using the International. Classification of Diseases Tenth Revision. Emerging Themes in Epidemiology. 2011; 8:1-45.

  7. Traumatic Brain Injury In the United States. Department of Health and Human Services Centers for Disease Control and Prevention. Emergency Department Visits, Hospitalizations and Deaths 2002-2006. Revisado en Junio 1, 2011, Disponible en: http://www.cdc.gov/TraumaticBrainInjury

  8. Suleiman GH. Trauma Craneoencefálico Severo: Parte I. Medicrit. 2005; 2:107-48.

  9. Ronald MR, Grant LI, Jeffrey TB, et al. Recommendations for Diagnosing a Mild Traumatic Brain Injury: A National Academy of Neuropsychology Education Paper. Archives of Clinical Neuropsychology. 2009; 24:3-10.

  10. XiongY, Mahmood A, Chopp M. Emerging treatments for traumatic brain injury. NIH Public Access Neurotherapeutics. 2009;14:67-84.

  11. Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic injury in adults. Lancet Neurology. 2008;7:728-41.

  12. Nestler EJ, Hyman SE, Malenka RC. Seizures and Stroke. In: Molecular Neuropharmacology. A foundation for clinical neuroscience. McGraw-Hill, NY. 2000; p 479-503.

  13. Beauchamp K, Haitham M, Wade RS, et al. Pharmacology of Traumatic Brain Injury: Where Is the “Golden Bullet”? Mol Med. 2008;14:731-40.

  14. Sacchetti ML, Toni D, Fiorelli M, Argentino C, Fieschi C. The concept of combination therapy in acute ischemic stroke. Neurology 1997;49(Suppl):70-4.

  15. Muir KW, Grosset DG. Neuroprotection for acute stroke making clinical trials work. Stroke. 1999;30:180-2.

  16. Barnes DM. Drug may protect brains of heart attack victims. Science. 1987;235(4789):632-3.

  17. Gagliardi RJ. Neuroprotection, Excitotoxicicity and NMDA antagonists. Arq Neuropsiquiatr. 2000;58(2-b):583-8.

  18. Olsen RW, DeLorey TM. GABA and Glycine. In: Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 6th Ed., edited by G. J. Siegel et al. Published by Lippincott-Raven Publishers Philadelphia.1999.

  19. Green AR, Hainsworth AH, Jackson DM. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology. 2000;39:1483-94.

  20. Hutchinson PJ, O’Connell MT, Al-Rawi PG, et al. Increases in GABA concentrations during cerebral ischaemia: a microdialysis study of extracellular amino acids. J Neurol Neurosurg Psychiatry. 2002;72:99-105.

  21. O’Dell DM, Gibson CJ, Wilson MS, et al. Positive and negative modulation of the GABA receptor and outcome after a traumatic brain injury in rats. Brain Research. 2000;861: 325-32.

  22. Fernández FJ, Hernández F, Argandoña L, et al. Farmacología de la neuroprotección en el ictus isquémico agudo. Rev Neurol. 2008;47:253-60.

  23. Hardingham GE. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans. 2000;937(Pt 6):1147-60.

  24. Gaspar T, Snipes JA, Busija AR, et al. ROS-independent preconditioning in neurons via activation of mitoKATP channels by BMS-191095. J Cereb Blood Flow Metab. 2008;28: 1090-103.

  25. Stein DG, Wright DW. Progesterone in the clinical treatment of acute traumatic brain injury. Expert Opin Investig Drugs. 2010;19(7):847-57.

  26. Akk G, Covey D, Evers A, et al.. Kinetic and structural determinants for GABA-A Receptor potentiation by neuroactive steroids. Current Neuropharmacology. 2010;8(1):18-25.

  27. Mathew BC, Biju RS. Neuroprotective Effects of Garlic, A Review. Libyan J Med. 2010.

  28. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options. Current Neuropharmacology. 2009;7(1):65-74.

  29. Shohami E, Cohen A, et al. Endocannabinoids and traumatic brain injury. Br J Pharmacol. 2011; Mar 21. doi: 10.1111/j.1476-5381.2011.01343.x. [Epub ahead of print].

  30. Hurley SD, Olschowka JA, O’Banion MK. Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J. Neurotrauma. 2002;19:1-15.

  31. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial Lancet. 2004;364:1321-8.

  32. Crack PJ, Gould J, Bye N, et al. The genomic profile of the cerebral cortex after closed head injury in mice: effects of minocycline. J Neural Transm. 2009;116:1-12.

  33. Piomelli D .The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4:873-84.

  34. Nadler V, Mechoulam R, Sokolovsky M. Blockade of 45Ca2+influx through the N-methyl-D-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211. Brain Res 1993;622:79-85.

  35. Pharmos Corporation. Dexanabinol did not demonstrate efficacy (2004) [online], http://www.pharmoscorp.com/news/pr/pr122004.html

  36. Royo NC, Conte V, Saatman KE, et al. Hippocampal vulnerability following traumatic brain injury: a potential role for neurotrophin-4=5 in pyramidal cell neuroprotection. Eur J Neurosci. 2006;23:1089-102.

  37. Kizhakke S, Evans H. Temporal and regional changes in IGF-1/IGF1R signaling in the mouse brain after Traumatic Brain Injury. J. of Neurotrauma. 2010;27:95-107.

  38. Blaha GR, Raghupathi R, Saatman KE, McIntosh TK. Brain derived neurotrophic factor administration after traumatic brain injury in the rat does not protect against behavioral or histological deficits. Neuroscience. 2000;99(3):483-93.

  39. Lu XC, Chen RW, Yao C, Wei H, Yang X, Liao Z, Dave JR, Tortella FC. NNZ-2566, a glypromate analog, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury. J Neurotrauma. 2009;26(1):141-54.

  40. Temkin NR, Anderson GD, Winn HR, et al. Magnesium sulfate for neuroprotection after traumatic brain injury: A randomised controlled trial. Lancet Neurol. 2007;6:29-38.

  41. Pemberton PL, Dinsmore J. The use of hypothermia as a method of neuroprotection during neurosurgical procedures and after traumatic brain injury: A survey of clinical practice in Great Britain and Ireland. Anaesthesia. 2003;58:363-84.

  42. Christian E, Zada G, Sung G, Giannotta SL. A review of selective hypothermia in the management of traumatic brain injury. Neurosurg Focus. 2008 Oct;25(4):E9

  43. Zafonte R, Friedewald WT, Lee SM, et al. The citicoline brain injury treatment (COBRIT) trial: design and methods. Journal of Neurotrauma. 2009;26:2207-16

  44. ATLS. Programa Avanzado de Apoyo Vital en Trauma para Médicos. Colegio Americano de Cirujanos. 7ª Edición.

  45. Martinez M, González R, Soto M, et al. Recovery after a traumatic brain injury depends on diurnal variations. Effect of cystatin C. Neuroscience Letters. 2006;400:21-4.




2020     |     www.medigraphic.com